Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-upJose. C. Villasboas,Tae Min Kim,Michal Taszner,Silvana Novelli,Seok-Goo Cho,Michele Merli,Ana Jimenez Ubieto,Benoit Tessoulin,Michelle Poon, Jan Walewski, Shuhua Yi,Yuqin Song,Geoffrey Chong, Stefano Luminari,Emmanuel Bachy,Stephanie Guidez,Aranzazu Alonso,Deepa Jagadeesh,Wei Zhang,Laura Magnano, Elzbieta Iskierka-Jazdzewska,Monica Tani, Jessica Cai,Amulya Uppala, Saleem Shariff,Lei Chi,Aafia Chaudhry,Hesham Mohamed,Srikanth Ambati,David TuckerBLOOD(2023)引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要